In a study, LIBTAYO was proven to help patients with advanced NSCLC live longer versus chemotherapy.

The study was designed to include patients if their tumor tested positive for the biomarker PD-L1 at a level greater than or equal to 50% and if they did not have abnormal EGFR, ALK, or ROS1 genes.

Half of the patients taking LIBTAYO (178 out of 356 patients) were alive at 22.1 months, compared with 14.3 months for patients taking chemotherapy (177 out of 354 patients).

Results showed that 248 out of 356 patients (70%) taking LIBTAYO were alive, compared with 213 out of 354 patients (60%) taking chemotherapy.

View full study overview and results

Learn about non–small cell lung cancer (NSCLC), including advanced NSCLC, and how it is diagnosed.

What is NSCLC,
including advanced NSCLC?